![Graeme Bell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Graeme Bell
Amministratore Delegato presso Valo Health, Inc.
Posizioni attive di Graeme Bell
Società | Posizione | Inizio | Fine |
---|---|---|---|
Cytoimmune Therapeutics, Inc.
![]() Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Direttore/Membro del Consiglio | 01/03/2023 | - |
Valo Health LLC
![]() Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | Amministratore Delegato | 16/01/2024 | - |
Direttore Finanziario/CFO | 01/08/2020 | - | |
Ufficiale delle Risorse Umane | 01/10/2022 | - | |
Valo Health, Inc.
![]() Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | Amministratore Delegato | 15/01/2024 | - |
Direttore Finanziario/CFO | 01/08/2020 | - | |
Ufficiale delle Risorse Umane | 01/10/2022 | - |
Storia della carriera di Graeme Bell
Precedenti posizioni note di Graeme Bell
Società | Posizione | Inizio | Fine |
---|---|---|---|
Tmunity Therapeutics, Inc.
![]() Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Direttore Finanziario/CFO | 01/09/2018 | 01/06/2020 |
INTELLIA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 15/09/2017 | 03/08/2018 |
Direttore Finanziario/CFO | 12/12/2016 | 03/08/2018 | |
ANACOR PHARMACEUTICALS INC | Comptroller/Controller/Auditor | 01/06/2015 | 01/11/2016 |
Direttore Finanziario/CFO | 01/06/2015 | 01/11/2016 | |
MERCK & CO., INC. | Public Communications Contact | 04/01/2007 | 04/11/2009 |
Direct Group Ltd.
![]() Direct Group Ltd. Insurance Brokers/ServicesFinance Direct Group Ltd. provides insurance services. Its products include property, motor, casualty, and life insurance. The company was founded in 1990 and is headquartered in Doncaster, the United Kingdom. | Corporate Officer/Principal | 03/03/2010 | - |
Formazione di Graeme Bell
University of Durham | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Regno Unito | 3 |
Posizioni
Director of Finance/CFO | 5 |
Comptroller/Controller/Auditor | 2 |
Chief Executive Officer | 2 |
Settori
Health Technology | 5 |
Finance | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
INTELLIA THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Direct Group Ltd.
![]() Direct Group Ltd. Insurance Brokers/ServicesFinance Direct Group Ltd. provides insurance services. Its products include property, motor, casualty, and life insurance. The company was founded in 1990 and is headquartered in Doncaster, the United Kingdom. | Finance |
Anacor Pharmaceuticals LLC
![]() Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Tmunity Therapeutics, Inc.
![]() Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
Cytoimmune Therapeutics, Inc.
![]() Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Health Technology |
Valo Health LLC
![]() Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | Technology Services |
Valo Health, Inc.
![]() Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | Finance |
- Borsa valori
- Insiders
- Graeme Bell
- Esperienza